Combining with these novel methylation markers associated with HCC early recurrence, we successfully established a methylation prediction model to distinguish ER from RF with superior performance compared with some current predictors, including tumor size, AFP, and BCLC. The gene discussed is AFP; the disease is hepatocellular carcinoma.